Hepatocellular Carcinoma Panel

The Hepatocellular Carcinoma Panel test contains 1 test with 3 biomarkers.

HCC Risk Panel includes serum AFP-L3%, total AFP and DCP. The combined measurement helps discriminate benign and malignant conditions related to primary liver diseases [1-4]. Furthermore, the combination measurement of three HCC biomarkers can identify a greater number of patients at risk of developing HCC than with each marker alone.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

AFP

AFP is used as a tumor marker to help detect and diagnose cancers of the liver, testes, and ovaries. Though the test is often ordered to monitor people with chronic liver diseases such as cirrhosis, chronic hepatitis B or hepatitis C because they have an increased lifetime risk of developing liver cancer. If a person has been diagnosed with hepatocellular carcinoma or another form of AFP-producing cancer, an AFP test may be ordered periodically to help monitor the person's response to therapy and to monitor for cancer recurrence.

AFP-L3

An AFP-L3% is sometimes also ordered to compare the amount of the AFP variant called AFP-L3 to the total amount of AFP. The test is used to help evaluate the risk of developing hepatocellular carcinoma, especially in those with chronic liver disease, and also to evaluate response of hepatocellular carcinoma to treatment.

Dcp (Des Gamma Carboxy

*Process times are an estimate and are not guaranteed. The lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.

Customer Reviews